Skip to main content
Moleculin submits new annamycin patent applications
7/11/2019

A new set of patent applications has been filed by Moleculin Biotech with the FDA regarding annamycin's production and reconstitution, which would protect the company's drug for another 20 years if approved. Annamycin is indicated as a treatment of relapsed or refractory acute myeloid leukemia.

Full Story: